ValiRx (LSE:VAL) Total Liabilities : £0.12 Mil (As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is ValiRx Total Liabilities?

ValiRx's Total Liabilities for the quarter that ended in Jun. 2023 was £0.12 Mil.

ValiRx's quarterly Total Liabilities declined from Jun. 2022 (£0.33 Mil) to Dec. 2022 (£0.15 Mil) and declined from Dec. 2022 (£0.15 Mil) to Jun. 2023 (£0.12 Mil).

ValiRx's annual Total Liabilities declined from Dec. 2020 (£0.18 Mil) to Dec. 2021 (£0.11 Mil) but then increased from Dec. 2021 (£0.11 Mil) to Dec. 2022 (£0.15 Mil).

ValiRx Total Liabilities Historical Data

The historical data trend for ValiRx's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Total Liabilities Chart

ValiRx Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

Get a 7-Day Free Trial

1.20

1.38

0.18

0.11

0.15

ValiRx Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Liabilities	Get a 7-Day Free Trial															0.13	0.11	0.33	0.15	0.12

ValiRx Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ValiRx's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.128	+	(0.022	+	-6.9388939039072E-18
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.15

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	3.976	-	3.826
	=	0.15

ValiRx's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.103	+	(0.017	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.12

Total Liabilities	=	Total Assets (Q: Jun. 2023 )	-	Total Equity (Q: Jun. 2023 )
	=	4.072	-	3.953
	=	0.12

ValiRx Total Liabilities Related Terms

Thank you for viewing the detailed overview of ValiRx's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx (LSE:VAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

EAJF:Germany

Address

4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.